Next Article in Journal
Emerging Strategies Targeting Catabolic Muscle Stress Relief
Next Article in Special Issue
A Timing Effect of 17-β Estradiol on Atherosclerotic Lesion Development in Female ApoE−/− Mice
Previous Article in Journal
Aldosterone Induces DNA Damage and Activation of Nrf2 Mainly in Tubuli of Mouse Kidneys
Previous Article in Special Issue
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
Open AccessArticle

Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)

Almazov National Medical Research Centre, St Petersburg 197341, Russia
Sechenov Institute of Evolutionary Physiology and Biochemistry of RAS, St Petersburg 194223, Russia
Institute of Translational Medicine, ITMO University, St Petersburg 197101, Russia
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(13), 4680;
Received: 1 June 2020 / Revised: 22 June 2020 / Accepted: 28 June 2020 / Published: 30 June 2020
(This article belongs to the Special Issue Pathomechanisms of Atherosclerosis. Part II)
Lipoprotein (a) (Lp(a)) is considered a genetic factor for cardiovascular disease playing an important role in atherogenesis and thrombosis, but the evidence about its association with sleep duration is controversial. We evaluated the relation between self-reported sleep duration and Lp(a). Among 1600 participants of the population-based sample, we selected 1427 subjects without previously known cardiovascular events, who answered the questions about their sleep duration; had valid lipid profile results (total cholesterol, low- and high-density lipoproteins, Lp(a), apolipoprotein AI (ApoAI), ApoB, and ApoB/ApoAI); and did not take lipid-lowering drugs (mean age 46 ± 12 years). We performed a structured interview, which included questions about lifestyle, medical history, complaints, and sleep duration (How long have you been sleeping per night during the last month?). Sleep duration was classified as follows: <6 h/night—short, 6–9 h/night—normal, and ≥10 h/night—long. Overall, 73 respondents (5.2%) were short-sleepers and 69 (4.8%) long-sleepers. Males were slightly more prevalent among short-sleepers. The groups matched by age, body mass index, blood pressure, diabetes mellitus, and hypertension rate. Short-sleepers had lower rates of high total cholesterol (≥5.0 mmol/L), lower Lp(a) levels and lower rates of increased Lp(a) ≥0.5 g/L, and higher insulin and insulin resistance (assessed by the homeostatic model assessment for insulin resistance (HOMA-IR)). ApoAI, ApoB, their ratio, and other lab tests were similar in the groups. The multinomial logistic regression demonstrated that only the short sleep duration was independently (odds ratio (OR) 0.29, 95% confidence interval (CI) (0.09–0.91), p = 0.033) associated with Lp(a) (χ2 = 41.58, p = 0.003). Other influencing factors were smoking and HOMA-IR. Such an association was not found for long-sleepers. In conclusion, a short-sleep duration is associated with Lp(a). The latter might mediate the higher insulin resistance and higher cardiometabolic risks in short-sleepers. View Full-Text
Keywords: sleep; sleep duration; cardiovascular risk; dyslipidemia; lipoprotein (a); insulin resistance sleep; sleep duration; cardiovascular risk; dyslipidemia; lipoprotein (a); insulin resistance
Show Figures

Figure 1

MDPI and ACS Style

Korostovtseva, L.; Alieva, A.; Rotar, O.; Bochkarev, M.; Boyarinova, M.; Sviryaev, Y.; Konradi, A.; Shlyakhto, E. Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a). Int. J. Mol. Sci. 2020, 21, 4680.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop